| Name | Ritonavir |
| Description | Ritonavir (ABT 538) is a peptidomimetic agent that inhibits both HIV-1 and HIV-2 proteases. Ritonavir is highly inhibited by serum proteins but boosts the effect of other HIV proteases by blocking their degradation by cytochrome P450. |
| In vivo | Ritonavir is a potent inhibitor of CYP3A-mediated biotransformation (terfenadine hydroxylation, IC50 of 0.14 mM; 17alpha-ethynylestradiol 2-hydroxylation, IC50 of 2 mM; nifedipine oxidation, IC50 of 0.07 mM).Ritonavir is a a potent inhibitor of CYP3A4-mediated testicular 6β-hydroxylation (Ki: 19 nM), and also inhibited hydroxylation by toluenesulfonylurea (IC50: 4.2 μM).Ritonavir also inhibited CYP2D6 (IC50: 2.5 mM) and CYP2C9/10 (IC50: 8.0 mM)-mediated responses.Ritonavir Ritonavir increased the cellular activity of uninfected human PBMC cultures.Ritonavir inhibited p-glycoprotein-mediated saquinavir solubilization (IC50: 0.2 μM), suggesting that Ritonavir has a high affinity for p-glycoprotein.Ritonavir significantly inhibited the metabolism of human hepatic microsomes ABT-378 (Ki: 13 nM). Ritonavir binding to ABT-378 ( in 3:1 and 29:1 ratios) was able to inhibit CYP3A (IC50: 1.1 and 4.6 μM). In cultures of uninfected human PBMCs, Ritonavir significantly reduced the susceptibility of PBMCs to apoptosis (associated with low levels of caspase-1 expression), decreased caspase-3 activity, and reduced membrane-bound protein staining. Ritonavir inhibited the induction of tumor necrosis factor produced by PBMCs and monocytes at nontoxic concentrations in a time- and dose-dependent manner. |
| Storage | store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Corn Oil : 2.5 mg/mL (3.47 mM), Sonication is recommeded.
DMSO : 242.5 mg/mL (336.37 mM), Heating is recommended.
Ethanol : 7.21 mg/mL (10 mM), Sonication is recommended.
|
| Keywords | SARS-CoV | SARSCoV | SARS coronavirus | Ritonavir | Inhibitor | inhibit | Human immunodeficiency virus | HIVProtease | HIV Protease | HIV | Apoptosis | ABT-538 | ABT538 | A-84538 | A84538 |
| Inhibitors Related | Stavudine | Emtricitabine | Cysteamine hydrochloride | Sodium 4-phenylbutyrate | L-Ascorbic acid | Hydroxychloroquine | Lamivudine | L-Glutamic acid | Tributyrin | L-Ascorbic acid sodium salt | Alginic acid | Dextran sulfate sodium salt (MW 5000) |
| Related Compound Libraries | Bioactive Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
